Article Versions Notes

Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, et al. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers. 2020; 12(4):1010. https://doi.org/10.3390/cancers12041010

Iwamoto, Hideki, Hiroyuki Suzuki, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Shusuke Okamura, Yu Noda, Naoki Kamachi, Toru Nakamura, and et al. 2020. "Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events" Cancers 12, no. 4: 1010. https://doi.org/10.3390/cancers12041010

Iwamoto, H., Suzuki, H., Shimose, S., Niizeki, T., Nakano, M., Shirono, T., Okamura, S., Noda, Y., Kamachi, N., Nakamura, T., Masuda, A., Sakaue, T., Tanaka, T., Nakano, D., Sakai, M., Yamaguchi, T., Kuromatsu, R., Koga, H., & Torimura, T. (2020). Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers, 12(4), 1010. https://doi.org/10.3390/cancers12041010